Sphera Funds Management’s Palisade Bio PALI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.33M Buy
2,464,038
+206,932
+9% +$404K 0.47% 74
2026
Q2
$4.72M Buy
2,257,106
+523,635
+30% +$1.03M 0.62% 52
2026
Q1
$3.03M Buy
1,733,471
+1,549,371
+842% +$2.82M 0.48% 65
2025
Q4
$433K Buy
+184,100
New +$354K 0.08% 91

Other funds holding PALI

Sphera Funds Management's PALI Position: Q3 2026 in Review

Sphera Funds Management increased its Palisade Bio (PALI) stake by 9.2% in Q3 2026, buying an estimated $404K and bringing the position to 2,464,038 shares worth $3.33M. The position accounts for 0.47% of the portfolio, ranked #74.

Sphera Funds Management first reported a position in PALI in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.72M in Q2 2026. 114 funds tracked by Wall St. Rank hold PALI as of Q3 2026.

  • Sphera Funds Management held 2,464,038 shares of Palisade Bio worth $3.33M as of Q3 2026.
  • Sphera Funds Management bought 206,932 Palisade Bio shares in Q3 2026, an estimated $404K.
  • Palisade Bio made up 0.47% of Sphera Funds Management's portfolio in Q3 2026, its #74 holding.
  • Sphera Funds Management first reported a position in Palisade Bio in Q4 2025 and has held it in 4 quarters since.
  • Sphera Funds Management's Palisade Bio position peaked at $4.72M in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2026.

Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.